TD Cowen Initiates Coverage On RAPT Therapeutics with Buy Rating

Benzinga · 2d ago
TD Cowen analyst Yaron Werber initiates coverage on RAPT Therapeutics (NASDAQ:RAPT) with a Buy rating.